Biogen was founded in 1978 and is headquartered in Cambridge, US

CEO

Biogen has an office in Cambridge

Cambridge, US (HQ)

225 Binney St

Biogen's revenue was reported to be $2.8 b in Q1, 2017

USD

## Revenue (Q1, 2017) | 2.8 b |

## Net income (Q1, 2017) | 747.5 m |

## EBIT (Q1, 2017) | 1 b |

## Market capitalization (18-Aug-2017) | 59.8 b |

## Cash (31-Mar-2017) | 924 m |

Biogen's current market capitalization is $59.8 b.

- Source: Company Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 6.9 b | 9.7 b | 10.8 b | 11.4 b |

## Revenue growth, % | 40% | 11% | 6% | |

## R&D expense | (2 b) | |||

## General and administrative expense | (1.9 b) | |||

## Operating expense total | (3.9 b) | |||

## EBIT | 4.9 b | 5.2 b | ||

## EBIT margin, % | 45% | 45% | ||

## Income tax expense | 1.2 b | 1.2 b | ||

## Net Income | 1.9 b | 2.9 b | 3.6 b | 3.7 b |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 2.4 b | 2.5 b | 2.6 b | 2.6 b | 2.8 b | 2.7 b | 2.9 b | 3 b | 2.8 b |

## R&D expense | 447.3 m | 417.2 m | 460.5 m | 490.7 m | 519.9 m | 437.3 m | 473.1 m | 529 m | 423.4 m |

## General and administrative expense | 576.6 m | 570.4 m | 560.4 m | 491.9 m | 477.8 m | 497.3 m | 492.4 m | 462.7 m | 499.1 m |

## Operating expense total | 1 b | 987.6 m | 1 b | 982.6 m | 997.7 m | 934.6 m | 965.5 m | 991.7 m | 922.5 m |

## EBIT | 988.7 m | 1.2 b | 1.1 b | 1.2 b | 1.4 b | 1.4 b | 1.5 b | 1.4 b | 1 b |

## EBIT margin, % | 41% | 46% | 44% | 48% | 49% | 51% | 50% | 48% | 36% |

## Income tax expense | 268.5 m | 274.8 m | 281.9 m | 292.5 m | 330.1 m | 356.4 m | 353.6 m | 337 m | 239.2 m |

## Net Income | 723.1 m | 856.1 m | 820.2 m | 924.8 m | 1 b | 969.2 m | 1 b | 1 b | 747.5 m |

- Source: Company Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 602.6 m | 1.2 b | 1.3 b | 2.3 b |

## Accounts Receivable | 824.4 m | 1.3 b | 1.2 b | 1.4 b |

## Inventories | 659 m | 804 m | 893.4 m | 1 b |

## Current Assets | 3.2 b | 4.7 b | 6.7 b | 8.7 b |

## PP&E | 1.8 b | 1.8 b | 2.2 b | 2.5 b |

## Goodwill | 1.2 b | 1.8 b | 2.7 b | 3.7 b |

## Total Assets | 11.9 b | 14.3 b | 19.5 b | 22.9 b |

## Accounts Payable | 219.9 m | 229.2 m | 267.4 m | 279.8 m |

## Total Debt | 1.2 b | |||

## Current Liabilities | 1.8 b | 2.2 b | 2.6 b | 3.4 b |

## Total Liabilities | 10.7 b | |||

## Additional Paid-in Capital | 4 b | 4.2 b | ||

## Retained Earnings | 6.3 b | 9.3 b | 12.2 b | 15.1 b |

## Total Equity | 8.6 b | 10.8 b | 9.4 b | 12.1 b |

## Debt to Equity Ratio | 0.1 x | |||

## Debt to Assets Ratio | 0.1 x | |||

## Financial Leverage | 1.4 x | 1.3 x | 2.1 x | 1.9 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 863.2 m | 1.2 b | 1.5 b | 1.3 b | 4.1 b | 1.1 b | 1.4 b | 2.1 b | 924 m |

## Accounts Receivable | 1 b | 1.1 b | 1.4 b | 1.3 b | 1.3 b | 1.4 b | 1.3 b | 1.5 b | 1.5 b |

## Inventories | 715.9 m | 753.1 m | 825.3 m | 865.7 m | 918.9 m | 964.6 m | 996.4 m | 1 b | 921.6 m |

## Current Assets | 3.9 b | 4.4 b | 5.3 b | 5.6 b | 9.3 b | 7.2 b | 7.4 b | 8.1 b | 6.9 b |

## PP&E | 1.8 b | 1.7 b | 1.7 b | 1.8 b | 2 b | 2.3 b | 2.3 b | 2.4 b | 2.6 b |

## Goodwill | 1.4 b | 1.5 b | 1.8 b | 2.2 b | 2.4 b | 2.9 b | 3.2 b | 3.4 b | 3.6 b |

## Total Assets | 12.9 b | 13.7 b | 15.2 b | 16.8 b | 20.7 b | 20.7 b | 21.5 b | 22.1 b | 21.2 b |

## Accounts Payable | 224.9 m | 233.6 m | 236.1 m | 282.7 m | 251.2 m | 271.3 m | 225.9 m | 274 m | 316.4 m |

## Current Liabilities | 1.9 b | 1.9 b | 1.9 b | 2.6 b | 2.6 b | 2.8 b | 2.5 b | 2.5 b | 3 b |

## Additional Paid-in Capital | 4.1 b | 4.2 b | 4.2 b | 4.3 b | 1.3 b | 18.4 m | 69.1 m | ||

## Retained Earnings | 7.5 b | 8.4 b | 10.1 b | 11 b | 12 b | 13.2 b | 14.2 b | 15 b | 14.8 b |

## Total Equity | 9.6 b | 10.4 b | 11.7 b | 12.6 b | 10.6 b | 10.3 b | 11.4 b | 12.1 b | 11.5 b |

## Financial Leverage | 1.4 x | 1.3 x | 1.3 x | 1.3 x | 2 x | 2 x | 1.9 x | 1.8 x | 1.8 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | 1.9 b | 2.9 b | 3.6 b | 3.7 b |

## Depreciation and Amortization | 688.2 m | 600.4 m | 682.7 m | |

## Accounts Receivable | (130 m) | (510 m) | 29 m | (241.4 m) |

## Inventories | (240 m) | (190 m) | (170 m) | (165.6 m) |

## Purchases of PP&E | (246.3 m) | (287.8 m) | (643 m) | (616.1 m) |

## Cash From Investing Activities | (1.6 b) | (1.5 b) | (4.6 b) | (2.5 b) |

## Cash From Financing Activities | (716.5 m) | (755.9 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 723.1 m | 856.1 m | 820.2 m | 924.8 m | 1 b | 969.2 m | 1 b | 1 b | 747.5 m |

## Accounts Receivable | 1.3 b | 1.3 b | 1.4 b | 1.3 b | 1.5 b | 1.5 b | |||

## Inventories | 865.7 m | 918.9 m | 964.6 m | 996.4 m | 1 b | 921.6 m | |||

## Accounts Payable | 282.7 m | 251.2 m | 271.3 m | 225.9 m | 274 m | 316.4 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 379.8 k |

## Financial Leverage | 1.8 x |

Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016

- Source: SEC Filings

Source: 109 public H-1B filings from Biogen

December 20, 2016

Biogen shares dropped as much as 4.6% on news of his appointment Monday.

September 03, 2016

Early results suggest a treatment for root causes, not just symptoms.

August 04, 2016

(Reuters) - U.S. biotechnology company Biogen Inc has not received any formal expressions of interest from potential acquirers and is not actively soliciting takeover offers, according to a person familiar with the matter.

August 02, 2016

Both Merck and Allergan are reportedly exploring a buyout.